Liquidia Corporation (LQDA) shares rose 2.7% to $49.15 as of November 10, 2026, a moderate gain from the prior close of $47.87. BestStocks flagged the session as a major change for LQDA. The move is tied to an earnings miss. Below, we break down what changed for LQDA, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
Earnings Miss
Liquidia Corporation (LQDA) reported EPS of −$2.64 vs. consensus estimate of $0.96 for Q3 FY2026, missing by 375%. Next earnings scheduled for 2027-03-04 with a consensus EPS estimate of $0.12.
This summary describes the catalyst and move as first detected on Nov 10, 2026, 10:14 AM EST; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Material / EarningsLow confidence
Rel. volume
0.4×
Below Avg
Vs peers
—
No comparable peers
Market cap
$4.4B
NASDAQ Capital Market
Analyst target
$72
+47.2% vs price
Price chart
Oct 12 – Nov 10
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Liquidia Corporation investors
For Liquidia Corporation investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 2.7% session move; Positive price momentum. Weighing against that: Earnings missed expectations; Liquidia Corporation (LQDA) moved −8.44% from $45.71 to $41.85 on November 2, 2026. Wall Street's consensus price target sits at $72.36, implying +47.2% upside from $49.15. Over the past 90 days analysts logged 2 upgrades and 4 downgrades. BestStocks rates the overall signal quality low (57/100). With earnings roughly 114 days out, the next report is the most likely near-term test of the move.
LQDA price reaction
LQDA last traded at $49.15, up $1.28 (+2.67%) from the previous close of $47.87. The session traded on 0.4× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $26.81 and $49.15, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Liquidia Corporation (LQDA)
▼Latest catalyst·strengthens the bear case
The latest catalyst — an earnings miss — it strengthens the bear case.
The consensus analyst price target on Liquidia Corporation (LQDA) is $72.36, 47.2% above the recent $49.15. Over the past 90 days analysts logged 2 upgrades, 9 maintains, and 4 downgrades. Here is how the bullish and bearish cases on LQDA line up.
▲ The bullish case
+Wall Street's consensus price target of $72.36 implies +47.2% upside from $49.15.
+The Street's most bullish target is $130.00 (+164.5%).
+2 analyst upgrades in the past 90 days, most recently BTIG to Buy (2026-10-14).
+Positive 2.7% session move.
+Positive price momentum.
▼ The bearish case
−The most bearish analyst target is $33.00 (-32.9%).
−4 analyst downgrades in the past 90 days, most recently Wells Fargo to Equal Weight (2026-10-02).
−Earnings missed expectations.
−Liquidia Corporation (LQDA) moved −8.44% from $45.71 to $41.85 on November 2, 2026.
−Liquidia Corporation fell 15.16% to $25.67 after filing a material event (8-K) with the SEC today.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish
The latest catalyst moved the balance toward the bears — the hollow tick marks where it sat before.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 10, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Liquidia Corporation (LQDA) filed its 10-Q on 2026-11-10.
Material / Earnings2026-11-05-6.1%
Liquidia Corporation (LQDA) moved -6.10% from $47.38 to $44.49 on November 5, 2026, ahead of its Q3 2026 financial results scheduled for release on November 10, 2026. The decline follows a significant rally in late October driven by a global litigation settlement with United Therapeutics regarding YUTREPIA.
Material / Earnings2026-11-04+12.3%
Liquidia Corporation (LQDA) moved +9.37% from $43.32 to $47.38 on November 4, 2026, reaching a new 30-day high on volume 2.0x the 5-day average. The company is scheduled to report Q3 2026 financial results on November 10, 2026.
News2026-11-03+0.8%
Liquidia scheduled Q3 2026 financial results release for November 10, 2026.
Risk2026-11-02-7.1%
Liquidia Corporation (LQDA) moved −8.44% from $45.71 to $41.85 on November 2, 2026. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average, suggesting the decline occurred on typical trading activity.
Liquidia shares rose 6.06% to $42.09, extending gains from a major settlement with United Therapeutics that resolved all six pending patent, trade secret, and antitrust lawsuits against the company. According to Yahoo Finance and Investing.com, the agreement eliminated the threat of an injunction against Yutrepia (inhaled treprostinil), clearing a path for uninterrupted commercialization of its flagship pulmonary arterial hypertension drug. Volume remained below average at 0.44x the typical intraday pace.
Liquidia shares gained 6.05% to $38.55, continuing momentum from its October 14 global settlement with United Therapeutics that resolved patent litigation and cleared a major commercial risk for YUTREPIA (per web_catalyst synthesis). The $380.7 million settlement removed the litigation overhang; H.C. Wainwright subsequently raised its price target to $65. Volume of 1.8M shares is below average (0.44x) at this point in the session.
Material / Earnings2026-10-20+6.5%
Liquidia Corporation (LQDA) moved +7.23% to $36.35 on October 20, 2026, continuing a rally following its October mid-month announcement of a $380.7 million global settlement with United Therapeutics that resolved all six pending lawsuits. The settlement clears litigation risk and secures uninterrupted U.S. commercial sales of YUTREPIA, its pulmonary arterial hypertension treatment. HC Wainwright raised its price target to $65 from $58 following the legal resolution.
In-depth LQDA event analyses
Permanent, dated analyses of LQDA's most significant sessions.
LQDA rose 2.7% to $49.15. The move is associated with an earnings miss.
How much did LQDA stock rise?
LQDA gained 2.67% ($1.28) versus the prior close of $47.87, last trading at $49.15 on 0.4× average volume.
When is Liquidia Corporation's next earnings date?
LQDA's next earnings report is estimated for 2027-03-04 — about 114 days away.
What is the analyst price target for LQDA?
The consensus analyst price target for LQDA is $72.36, about 47.2% above the current $49.15. Over the past 90 days, analysts recorded 2 upgrades, 9 maintains, and 4 downgrades.
How BestStocks tracks LQDA
This page is generated automatically by BestStocks' change-detection system after an earnings miss was detected and verified against independent data sources. It draws on 20 tracked change events for LQDA, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 10, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
